Why biote Corp.’s (BTMD) Stock Is Down 17.48%
As of Thursday, August 06, biote Corp.’s BTMD share price has dipped by 17.48%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.
Commentary & Analysis
Why biote Corp.’s (BTMD) Stock Is Down 26.99%
As of Thursday, August 06, biote Corp.’s BTMD share price has dipped by 26.99%, which has investors questioning if this is right time to buy.Tudor Pop
Why biote Corp.’s (BTMD) Stock Is Up 6.86%
As of Thursday, July 30, biote Corp.’s BTMD share price has surged by 6.86%, which has investors questioning if this is right time to sell.Michael Rose
Why biote Corp.’s (BTMD) Stock Is Up 8.30%
As of Thursday, July 16, biote Corp.’s BTMD share price has surged by 8.30%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why biote Corp.’s (BTMD) Stock Is Up 6.53%
As of Thursday, July 02, biote Corp.’s BTMD share price has surged by 6.53%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | BTMD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $42.4 | $618.0 | 14% |
|
| Shares Out (Mil) | 28.6 | 44.8 | 36% |
|
| Institutional Ownership | 70.6% | 85.3% | 43% |
|
| Float (Mil) | 17.8 | 47.4 | 27% |
|
| Beta | 1.65 | 0.70 | 87% |
|
| Avg Daily Volume (000s) | 390 | 390 | 54% |
|
| Price Change (52-week) |
(51.0%) | 68.6% | 14% |
|
| Growth | BTMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 10.5% | 6.7% | 60% |
|
| Net Income (5yr) | (1.6%) | (1.6%) | 38% |
|
| EPS (5yr) | (52.2%) | 14.9% | 3 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.7%) | (14.9%) | 47% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | $0.040 | $0.350 | $0.450 | |
| Month Ago EPS | $0.120 | $0.490 | $0.570 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | $0.120 | $0.490 | $0.570 | |
| Year/Year Chg | (117.4%) | (52.7%) | (32.4%) | |
| Financials | BTMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $184 | $291 | 31% |
|
| Net Income (TTM) (Mil) | $6 | ($11) | 43% |
|
| EPS (TTM) | $0.193 | ($0.700) | 46% |
|
| Operating Cash Flow (TTM) (Mil) | $24 | ($6) | 42% |
|
| Net Cash Flow (TTM) (Mil) | ($8) | $5 | 31% |
|
| Long-Term Debt (Q1) (Mil) | $125 | $6 | 46% |
|
| Enterprise Value (Q1) (Mil) | $164 | $450 | 25% |
|
| Valuation | BTMD | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.78 | na |
|
| P/E | 8.2 | 17.4 | 11% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BTMD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 69.4% | 67.0% | 80% |
|
| Net Margin | 3.2% | (2.3%) | 42% |
|
| ROA | 5.7% | (22.4%) | 75% |
|
| ROE | (7.8%) | (20.2%) | 29% |
|
| Liabilities to Assets | 157.2% | 32.2% | 98% |
|
| F-Score | 5 | 3 | 50% |
|
biote Corp. did not pass any screens on 8/20/2026.
